Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Ortho Biotech Products, L.P. |
---|---|
Information provided by: | Ortho Biotech Products, L.P. |
ClinicalTrials.gov Identifier: | NCT00350090 |
The purpose of this study is to evaluate the effectiveness and safety of PROCRIT (Epoetin alfa) administered at 40,000 Units weekly in cancer patients that are not receiving chemotherapy or radiation therapy.
Condition | Intervention | Phase |
---|---|---|
Neoplasms Anemia |
Drug: Epoetin Alfa |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Pilot Study to Evaluate the Response Rate of PROCRIT (Epoetin Alfa) at 40,000 Units Once Weekly in Anemic Cancer Patients Not Receiving Chemotherapy |
Estimated Enrollment: | 100 |
Study Start Date: | May 2003 |
Study Completion Date: | March 2004 |
This is an open-label (both the researcher and the patient in the study know the treatment that is being given), non-randomized, multi-center pilot study with the objective to investigate the efficacy of PROCRIT (Epoetin alfa) with regard to hematopoietic response when administered at 40,000 Units subcutaneously (under the skin) once per week in anemic patients with cancer not receiving chemotherapy or radiation therapy. Hematological laboratory tests (hemoglobin and hematocrit), vital signs (blood pressure) and occurrence and severity of adverse events will be assessed throughout the study.
Patients will receive a PROCRIT (Epoetin alfa) injection (40,000 Units per injection) under the skin once every week for a maximum of 13 weeks. Doses may be reduced depending on the patients' hemoglobin level.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CR005113 |
Study First Received: | July 7, 2006 |
Last Updated: | December 4, 2007 |
ClinicalTrials.gov Identifier: | NCT00350090 |
Health Authority: | United States: Institutional Review Board |
Anemia Neoplasms Hemoglobin values |
Epoetin Alfa Hematologic Diseases Anemia |
Neoplasms Hematinics Therapeutic Uses Hematologic Agents Pharmacologic Actions |